id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-E-0092-0012,FDA,FDA-2008-E-0092,"U.S. Patent and Trademark Office to Heslin, Rothenberg, Farley & Mesiti, P.C. - Letter",Other,Letter(s),2012-06-13T04:00:00Z,2012,6,2012-06-13T04:00:00Z,,2012-06-13T12:50:01Z,,0,0,09000064810428e6
FDA-2008-E-0092-0011,FDA,FDA-2008-E-0092,FDA/CDER to U.S. Patent and Trademark Office - Letter,Other,Letter(s),2012-03-16T04:00:00Z,2012,3,2012-03-16T04:00:00Z,,2012-03-16T18:36:12Z,,0,0,0900006480fd9230
FDA-2008-E-0092-0010,FDA,FDA-2008-E-0092,Determination of Regulatory Review Period for Purposes of Patent Extensions: XYZAL,Notice,General Notice,2011-06-24T04:00:00Z,2011,6,2011-06-24T04:00:00Z,,2011-06-24T18:41:42Z,2011-15910,0,0,0900006480eb33fd
FDA-2008-E-0092-0009,FDA,FDA-2008-E-0092,FDA\CDER to United States Patent and Trademark Office - Letter,Other,LET-Letter,2011-06-03T04:00:00Z,2011,6,2011-06-03T04:00:00Z,,2011-06-03T16:27:45Z,,0,0,0900006480e3a989
FDA-2008-E-0092-0008,FDA,FDA-2008-E-0092,USPTO to FDA/CDER - Letter,Other,LET-Letter,2010-12-21T05:00:00Z,2010,12,,,2010-12-27T18:50:57Z,,0,0,0900006480bbcf60
FDA-2008-E-0092-0005,FDA,FDA-2008-E-0092,Exhibit C [Maintenance Fee Payment],Supporting & Related Material,APP-Application,2008-02-11T05:00:00Z,2008,2,,,2008-04-11T22:38:39Z,,0,0,09000064803aca64
FDA-2008-E-0092-0001,FDA,FDA-2008-E-0092,Sepracor Inc. - Patent Term Extension Application,Other,APP-Application,2008-02-11T05:00:00Z,2008,2,2008-02-11T05:00:00Z,,2008-04-11T22:38:38Z,,0,0,09000064803a9375
FDA-2008-E-0092-0002,FDA,FDA-2008-E-0092,USPTO -  Letter,Other,LET-Letter,2008-02-11T05:00:00Z,2008,2,2008-02-11T05:00:00Z,,2008-04-11T22:38:39Z,,0,0,09000064803a9386
FDA-2008-E-0092-0006,FDA,FDA-2008-E-0092,Exhibit D [Maintenance Fee Payment],Supporting & Related Material,APP-Application,2008-02-11T05:00:00Z,2008,2,,,2008-04-11T22:38:38Z,,0,0,09000064803aca6c
FDA-2008-E-0092-0003,FDA,FDA-2008-E-0092,Exhibit A [UCB Pharma S.A. Authorization Letter],Supporting & Related Material,APP-Application,2008-02-11T05:00:00Z,2008,2,,,2008-04-11T22:38:39Z,,0,0,09000064803aca5e
FDA-2008-E-0092-0007,FDA,FDA-2008-E-0092,Exhibit E [FDA Chronology of Significant Activities],Supporting & Related Material,APP-Application,2008-02-11T05:00:00Z,2008,2,,,2008-04-11T22:38:39Z,,0,0,09000064803aca71
FDA-2008-E-0092-0004,FDA,FDA-2008-E-0092,"Exhibit B [Copy of US Patent No. 5,698,558]",Supporting & Related Material,APP-Application,2008-02-11T05:00:00Z,2008,2,,,2008-04-11T22:38:39Z,,0,0,09000064803aca61